Skip to main content
Advertisement
Advertisement
EVO
EVO logo
Evotec SE - ADR
1.32
USD
Sponsored
-0.13
-8.97%
Nov 20, 15:56 UTC -5
Closed
exchange

After-Market

1.31

-0.01
-0.38%

Evotec SE - ADR (EVO) Earnings

EVO Earnings Reports

Positive Surprise Ratio

EVO beat 17 of 41 last estimates.

41%

Next Report

Date of Next Report
Apr 06, 2027
Estimate for Q4 26 (Revenue/ EPS)
$140.69M
/
-$0.44
Implied change from Q3 26 (Revenue/ EPS)
-14.69%
/
+193.33%
Implied change from Q4 25 (Revenue/ EPS)
-44.45%
/
-650.00%

Evotec SE - ADR earnings per share and revenue

On Nov 05, 2026, EVO reported earnings of -0.15 USD per share (EPS) for Q3 26, beating the estimate of -0.34 USD, resulting in a 56.32% surprise. Revenue reached 164.93 million, compared to an expected 130.29 million, with a 26.58% difference. The market reacted with a +13.06% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.44 USD, with revenue projected to reach 140.69 million USD, implying an increase of 193.33% EPS, and decrease of -14.69% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Apnimed, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.62
Actual
-$0.99
Surprise
-59.11%
logo
Larimar Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.35
Actual
-$0.28
Surprise
+17.38%
logo
Lexeo Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.33
Actual
-$0.43
Surprise
-28.17%
logo
Galectin Therapeutics Inc.
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.05
Actual
-$0.04
Surprise
+21.57%
logo
NRX Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.21
Actual
-$0.05
Surprise
+76.94%
logo
Unicycive Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.32
Actual
-$0.25
Surprise
+21.88%
logo
Actinium Pharmaceuticals, Inc
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.19
Surprise
+23.45%
logo
Marker Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.11
Actual
-$0.10
Surprise
+15.97%
logo
Scienture Holdings, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$1.60
Actual
-$3.76
Surprise
-134.79%
logo
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.74
Actual
-$0.75
Surprise
-0.73%
FAQ
For Q3 2026, Evotec SE - ADR reported EPS of -$0.15, beating estimates by 56.32%, and revenue of $164.93M, 26.58% above expectations.
The stock price moved up 13.06%, changed from $1.57 before the earnings release to $1.77 the day after.
The next earning report is scheduled for Apr 06, 2027.
Based on -- analysts, Evotec SE - ADR is expected to report EPS of -$0.44 and revenue of $140.69M for Q4 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement